Advanced Biomed (ADVB) Liabilities and Shareholders Equity (2024 - 2026)

Advanced Biomed has reported Liabilities and Shareholders Equity for 3 years, with the latest figure at $10.6 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 28.46% year-over-year to $10.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $41.5 million (up 140.31% YoY) and the FY2025 annual result came in at $13.7 million, up 207.56% from the prior year.
• Liabilities and Shareholders Equity declined to $10.6 million in Q1 2026 per ADVB's latest filing, from $10.9 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $13.7 million in Q2 2025 and troughed at $4.5 million in Q2 2024.
• A 3-year average of $8.4 million and a median of $8.3 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2025 and 2026: Liabilities and Shareholders Equity soared 207.56% in 2025, then advanced 28.46% in 2026.
• Over 3 years, Liabilities and Shareholders Equity stood at $4.5 million in 2024, then soared by 140.9% to $10.9 million in 2025, then decreased by 1.88% to $10.6 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $10.6 million, $10.9 million, and $6.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.